---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-130709"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2025-05-29T23:59:59+00:00"
generated_at: "2026-05-20T06:16:17.805677+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Taysha prices $187M stock offering; TSHA-102 achieves 100% milestone gain, FDA agrees on pivotal trial design

## Summary
- Issued 46.9M shares at $2.75/sh and 25.9M pre-funded warrants at $2.749; net proceeds ~$187.4M.
- Underwriters granted 30-day option for up to 10.9M additional shares; closing expected May 30.
- TSHA-102 in Rett syndrome: 100% (10/10) patients gained/regained ≥1 milestone post-treatment, with high dose outperforming low dose.
- FDA provided written alignment on single-arm pivotal Part B trial design; primary endpoint: developmental milestone gain/regain in patients ≥6 yrs.
- Astellas option to license TSHA-102 remains exercisable 90 days after receipt of Rett Data Package expected mid-2025.

## SEC filing metadata
- accession: 0001193125-25-130709
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2025-05-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312525130709/0001193125-25-130709-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312525130709/d948981d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-130709
- JSON: https://secwatch.observer/filing/0001193125-25-130709.json
- Plain text: https://secwatch.observer/filing/0001193125-25-130709.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.